enterovirus 71 vaccine + recombinant hepatitis B vaccine + group A meningococcal polysaccharide vaccine

The enterovirus 71 vaccine + recombinant hepatitis B vaccine + group A meningococcal polysaccharide vaccine is a trivalent combination vaccine candidate developed by Beijing Minhai Biotechnology. It is designed to provide simultaneous protection against three distinct infectious diseases in pediatric populations: Hand, Foot, and Mouth Disease (HFMD) caused by Enterovirus 71 (EV71), Hepatitis B, and Meningococcal meningitis caused by Neisseria meningitidis serogroup A. The vaccine formulation incorporates an inactivated EV71 antigen (produced using human diploid cells), a recombinant Hepatitis B surface antigen (HBsAg), and the purified capsular polysaccharide of serogroup A meningococci. By combining these antigens into a single injection, the candidate aims to simplify the pediatric immunization schedule, improve vaccination compliance, and reduce the number of clinical visits. As of 2021, the vaccine was undergoing Phase 1 clinical evaluation in China to assess its safety and immunogenicity in healthy subjects aged 2 months and older.

Other names

enterovirus 71 vaccine + recombinant hepatitis B vaccine + group A meningococcal polysaccharide vaccineEV71-HepB-MenA combination vaccineEV-71-HepB-MenA combination vaccineEV 71-HepB-MenA combination vaccineEnterovirus Type 71, Hepatitis B (Recombinant) and Group A Meningococcal Polysaccharide Combined Vaccine (Human Diploid Cell)